Calidi Biotherapeutics Inc. Company Profile
NYSE: CLDIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 4:00 PM ET
Calidi Biotherapeutics at a glance
Calidi Biotherapeutics Inc. (NYSE: CLDI) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in San Diego, CA. Calidi Biotherapeutics is led by Dr. Eric E. Poma Ph.D. and employs about 29 people. The company's shares have traded publicly since 2021.
At a market capitalization of $3.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001855485, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Calidi Biotherapeutics do?
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Business description based on the company's public filings.
Company information
- Legal name
- Calidi Biotherapeutics Inc.
- Ticker
- NYSE: CLDI
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Eric E. Poma Ph.D.
- Employees
- 29
- Headquarters
- 4475 Executive Drive, San Diego, CA, United States
- Phone
- 858 794 9600
- Website
- calidibio.com
- IPO year
- 2021
- Market cap
- $3.82M
- SEC CIK
- 0001855485
Companies similar to Calidi Biotherapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SLXNSilexion Therapeutics Corp | 0.2286 | -2.68% | $3.31M | vs CLDI |
| PMCBPharmaCyte Biotech Inc. | 0.4082 | +1.09% | $4.38M | vs CLDI |
| VIVSVivoSim Labs Inc. | 0.177 | -0.11% | $2.94M | vs CLDI |
| LIMNLiminatus Pharma Inc. Class A | 3.69 | -4.65% | $4.96M | vs CLDI |
| HLSQTessera Defense and Homeland Security Inc. | 0.2957 | +3.57% | $2.67M | vs CLDI |
| CRISCuris Inc. | 0.72 | +1.49% | $1.75M | vs CLDI |
| SCNIScinai Immunotherapeutics Ltd. ADR | 1.21 | +7.08% | $1.64M | vs CLDI |
| CELZCreative Medical Technology Holdings Inc. | 0.8604 | -2.45% | $6.53M | vs CLDI |